Prognostic value of the Charlson index in mortality in patients with pulmonary embolism associated with cancer versus non-tumour pulmonary embolism

Abstract

IntroductionThe aim of this study is to analyse comorbidity, survival, and mortality from pulmonary embolism in people with cancer and without cancer. And to determine whether the Charlson Comorbidity Index (CCI) predicts mortality in the short and long term in this population. MethodsA retrospective observational study on survival in patients hospitalized in the Hospital Central de Defensa from 01/01/2009 to 15/03/2018, stratifying into tumour PE group (EPT) and non-tumour PE group (EPnT), all of whom were classified according to age adjusted CCI. Results368 patients were diagnosed with PE, 108 with associated cancer. The mean CCI in the EPT group was 7.2 and 4.5 in the EPnT group. Patients with PE and CCI > 5 were 10.7 times more likely to die (95%CI:1.5–77.6) compared to CCI 0 (P = .019). The CCI of patients with EPT was 2.6 points higher (95%CI:1.9–33) than EPnT patients (P < .001). Cancer patients were 1.9 times more likely to die (95%CI: 1.23–2.8) and had higher mortality at 30 days and at one year after the event, with a median survival of 8.98 years and 3.4 years, respectively (P < .001). ConclusionsThe CCI in EPT is an independent risk factor related to mortality. The CCI can predict higher mortality in the short and long term in patients with PE.